- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03235700
Hyperemic Efficacy of IV Adenosine in HFrEF (HF-FFR)
July 28, 2017 updated by: Sejong General Hospital
Hyperemic Efficacy of Intravenous Infusion of Adenosine in Heart Failure With Reduced Ejection Fraction
Little is known about the hyperemic efficacy of IV adenosine as well as safety in patients with heart failure with reduced ejection fraction (HFrEF) because they were excluded from the major FFR studies.
We will evaluate the feasibility and hyperemic efficacy of IV adenosine in patients with HFrEF in comparison with IC nicorandil for invasive physiological assessment using a coronary pressure wire.
Study Overview
Status
Unknown
Detailed Description
Little is known about the hyperemic efficacy of IV adenosine as well as safety in patients with heart failure with reduced ejection fraction (HFrEF) because they were excluded from the major FFR studies.
We will evaluate the feasibility and hyperemic efficacy of IV adenosine in patients with HFrEF in comparison with IC nicorandil for invasive physiological assessment using a coronary pressure wire.
Patients with an angiographically intermediate lesion (40-70% diameter stenosis) in a major epicardial coronary artery and with left ventricle ejection fraction ≤40% will be prospectively enrolled.
FFR under the various hyperemic stimulation using IV adenosine 140 & 180, IC adenosine, and IC nicorandil will be measured sequentially.
Study Type
Interventional
Enrollment (Anticipated)
125
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ho-Jun Jang, MD
- Phone Number: +82-32-340-1445
- Email: hojunjang77@gmail.com
Study Locations
-
-
Gyeonggi
-
Bucheon, Gyeonggi, Korea, Republic of, 422-711
- Recruiting
- Sejong general hospital, 91-121 Sosa 2-Dong, Sosa-Gu
-
Contact:
- Hyun-Jong Lee, MD
- Phone Number: 82-10-6217-9315
- Email: untouchables@sejongh.co.kr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- angiographically proven epicardial intermediate stenosis (40-70%)
- echocardiographically proven LV dysfunction (LVEF ≤40%)
Exclusion Criteria:
- infarct-related artery, less than 2 weeks
- Killip class 3 and 4
- bronchial asthma
- second degree or third degree AV block
- any contraindications to adenosine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Adenosine followed by nicorandil
|
IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
|
EXPERIMENTAL: Nicorandil followed by adenosine
|
IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Failure to induce maximal hyperemia
Time Frame: less than 1 day
|
no hyperemia, cyclic hyperemia, and submaximal hyperemia
|
less than 1 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fractional flow reserve
Time Frame: less than 1 day
|
less than 1 day
|
time to maximal hyperemia
Time Frame: less than 1 day
|
less than 1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 1, 2017
Primary Completion (ANTICIPATED)
February 28, 2020
Study Completion (ANTICIPATED)
February 28, 2020
Study Registration Dates
First Submitted
July 28, 2017
First Submitted That Met QC Criteria
July 28, 2017
First Posted (ACTUAL)
August 1, 2017
Study Record Updates
Last Update Posted (ACTUAL)
August 1, 2017
Last Update Submitted That Met QC Criteria
July 28, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Heart Failure
- Coronary Artery Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Purinergic Agents
- Micronutrients
- Vitamins
- Vitamin B Complex
- Purinergic P1 Receptor Agonists
- Purinergic Agonists
- Adenosine
- Nicorandil
Other Study ID Numbers
- 1642
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on Maximal hyperemia with adenosine followed by nicorandil
-
Seoul National University HospitalSeoul National University Boramae Hospital; Keimyung University Dongsan Medical... and other collaboratorsUnknownMyocardial Ischemia | Coronary Artery DiseaseKorea, Republic of
-
Wake Forest University Health SciencesTerminated
-
Tanta UniversityCompleted
-
Haukeland University HospitalMøre og Romsdal Hospital TrustActive, not recruitingLumbar Degenerative SpondylolisthesisNorway
-
Acutus MedicalCompletedSupraventricular TachycardiaUnited Kingdom, Canada, Czechia, Belgium, Chile, Germany
-
Acutus MedicalWithdrawnSupraventricular TachycardiaIreland
-
Robert Jones and Agnes Hunt Orthopaedic and District...Action Medical ResearchCompletedCerebral PalsyUnited Kingdom
-
Northern TherapeuticsOttawa Hospital Research InstituteActive, not recruiting
-
PROCEPT BioRoboticsCompletedBenign Prostatic HyperplasiaIndia